The main thing about the day's trading was the 71 point gain in NASDAQ. This generated a lot of short covering in ISIL and spiked it over $12. At that point, there was a lot of short term profit taking in lesser issues like ISIL as well as the shorts coming back in and shorting ISIL again as its technical strength weakened. Those 2 things drove the stock down as much as 8% at its nadir before buyers came back into the stock. I think this was its most unusual trading day since a day in January of 2013.
I don't know about the situation on 2/11/14, but the Goldman Sachs presentation is certainly running now. For some reason, the 2/10/14 Stifel presentation is given priority and one can't see the Goldman Sachs link unless they click on "click here for more events."
Either the $16.5 million for SG&A or $2.2 million for R&D is probably going to be higher this quarter because of the perclot trial. SG&A already averaged $17 million for the first 3 quarters of 2013. On the good side, there was 7% growth in sales for the 9 months and I certainly think they could cut SG&A by $5 million a quarter. I'm not sure how you're applying the 15% ROI. I notice you have lowered CRY's worth some in your calculation. What went down?
Well, the upcoming earnings spike is a one-time event caused by a stock sale. It's possible the company is making great strides toward getting perclot approved but I doubt it. The company took over 2 years just to get the investigational device exemption approved. That seems excessive especially if one considers the CEO once stated they would have perclot FDA approved by early 2013. However, I'm not the best source of information on medical device approval.
My figures were aimed at demonstrating the stock's recent volatility. Over a period of 4 months and 9 days, CRY rose 89%. So I wrote the stock was up almost 100% in 4 months. Since you want to be precise, the stock wasn't up "100% in 5 months" as you wrote. One has to go back over 9 months to get a gain of 100% at the January closing high.
Anyone want to take a guess as to why CRY is up 18% presently from its recent lows 5 weeks ago? Good news about the Perclot clinical trial? Their earnings estimate for the December quarter has more than doubled but that's because of the Medafor one-time stock sale. The estimates for the March, 2014 quarter and full year 2014 have actually declined slightly due to Perclot's clinical trial expenses being increased.